Try our Advanced Search for more refined results
Life Sciences - June, 2016
343 articles
- Horizon Fights Par Pharma's Generic Of Urine Disorder Drug
- Health Cos. Paid More To Charity, Nuclear Med Docs In 2015
- Del. Court Tosses $1.2B Philips-Volcano Merger Suit
- $45M Ends Medtronic-NuVasive Patent Saga
- GNC Can't Ax ThermoLife Patent Row
- CVS To Pay $3.5M For Filling 500 Forged Prescriptions
- Mylan Offers Antitrust Fixes To EU For $10B Meda Buy
- Some Fed. Circ. Guidance On Procedural Safeguards For PTAB
- How McDonnell Changes Public Corruption Prosecution
- A Serious Circuit Split On Class Ascertainability
- PerkinElmer Faces Suit Over 'Dismal' Drug Test Devices
- Fla. Co. Settles Abbot Test Strip RICO Suit For $9K
- Whistleblowing Ex-Mylan VP Settles Wrongful Firing Suit
- NY Should Unify Standards For Atty Fees Against State Agency
- Caisse Invests $222.9M In Products Testing Firm Eurofins
- RICO Claims Don't Hold Up In Abbott Off-Label Use Suit
- Affymetrix Investor Settles Suit Over $1.3B Thermo Fisher Sale
- FTC Urges Pa. Judge Not To Extend Deadline For Abbvie Docs
- Hawaii Escapes Plavix MDL Discovery Agreement
- DLA Piper Attys Lied Under Oath About Witness Calls: Judge
- Lamictal Pay-For-Delay Row Shouldn't Be Paused, Buyers Say
- Lipozene Buyer Seeks Class Cert. In False Advertising Row
- Heart Device Maker Pays $8M To End FCA Kickback Suit
- Medtronic Gets Bosch Patent Dismissals Upheld By Fed. Circ.
- Plavix FCA Suit Revived After High Court's Escobar Ruling
- DOJ Confirms Epic Spike In FCA Penalties
- USPTO To Expedite Reviews Of Cancer Treatment Patent Apps
- Arbitrators Overstepped In Biotech IP Row, 3rd Circ. Told
- 3rd Circ. Wants Arguments Limited To Market In Doryx Row
- Biologic Patents Are Under Attack
- 'Kickbacks' In FCA Suit Were Just Discounts, Omnicare Says
- Cooley Adds IP Pros From Pillsbury, MoFo To Calif. Offices
- Monsanto Still In Talks With Bayer After Rejecting $62B Bid
- How To Manage Your Law School Debt After Graduation
- Sanofi Junk Fax Class Asks For Cert In TCPA Row
- The 10 Firms GCs Love For Pharma Work
- 9th Circ. Partially Revives Supplement Suit Against GNC
- Accused 'Snake Oil' Tea Seller Enters Consent Decree
- High Court May Put Limits On Foreign Reach Of US Patents
- FDA, CDC Committee Clash Over Nasal Spray Flu Vaccine Use
- Acclarent Didn't Tell FDA About Adverse Events, Jury Told
- How To Become The Firm Every GC Wants To Hire
- NJ Blood Lab Cops To Role In $100M Referral Scheme
- Hogan Lovells Partner Among 18 Named To Calif. Bench
- The 24 Firms GCs Love The Most
- Celator Investor Looks To Block $1.5B Jazz Pharma Deal
- FDA Sued For Yanking Approval Of Generic Chemo Drug
- Indivior Scores Docs In Suboxone Product-Hopping MDL
- Ex-Zimmer Sales Rep Says Whistleblowing Got Him Canned
- Judge Signs Off On $1B Deal To End Vioxx Marketing Row
- New Vt. Drug Pricing Law Will Have A Limited Impact
- The Firms That Won Big At the Supreme Court
- Ranbaxy: Court Recognizes Fraud-On-The-FDA Antitrust Claim
- The Top Supreme Court Dissents Of The Term
- The Supreme Court Term By The Numbers
- The Funniest Moments Of The Supreme Court's Term
- J&J Unit's Bone Cement Killed Woman In Surgery, Jurors Hear
- A Divided Court Finds New Ways To Be Unanimous
- AstraZeneca Sues FDA To Stop Crestor Generics
- High Court Reins In DOJ With Tightened Bribery Standard
- 8 Wasn't Enough For Lawyers Seeking High Court Clarity
- Attorneys React To High Court's Political Bribery Ruling
- Wright Hip Implant Bellwether Must Be Retried, 11th Circ. Told
- High Court Won't Hear Patent Row Over Fetal DNA Test
- Acclarent Device Quickly Raised Alarms At FDA, Jury Told
- Deals Rumor Mill: China Resources Pharma, Apax, Kuka
- PE-Backed Clinical Trials Co. Medpace Files $150 IPO
- Tobacco Co. Sues Weed Cos. Over 'Marley' Trademark
- The Cloud And Ethical Considerations For Lawyers
- Hunton & Williams Adds IP, Hatch-Waxman Partner In DC
- Send Abilify Compulsive Gambling Suits To Fla.: Consumers
- Sanofi Investors Lose Bid To Revive Kickback Allegations
- Ropes Advises Medtronic's $1.1B Heart Tech Firm Purchase
- A Few Important Decisions From The 'Inferior' Courts
- High Court Vacates Ex-Va. Gov.'s Corruption Conviction
- Justices Will Hear Case On Overseas Reach Of Patent Law
- KaloBios, Shkreli Deal Gets Final OK In Bankruptcy Court
- Supreme Court Asked To Resolve Drug-Fraud RICO Split
- Pfizer Seeks Escape From Lipitor Diabetes MDL Claims
- Pharma Rep Takes Malicious Prosecution Suit To High Court
- Ex-Pharma CEO Says SEC Call For Banishment Too Harsh
- FDA Should Broaden Use Of Real-World Data, Report Says
- Actavis Opposes Further Doc Production In Suboxone MDL
- Biogen Escapes Investor Suit Over Growth Forecasts
- GE Unit Diluted Cell Growth Serum, Stole Buyers, Suit Says
- Watson Wants Lidoderm, Opana Pay-For-Delay Suits Split
- Creating A Partial Solution To Delayed Generic Competition
- How Lawyers Can Harness The Power Of Social Media
- J&J Tells 5th Circ. Hip Implant MDL Is Flawed
- USPTO Director Fires Back At Challenge To AIA Reviews
- Clerical Error Spurs $24M Deal To End Caris Merger Suit
- Norton Rose Fulbright Nabs Partner From Sheppard Mullin
- With Experts Barred, Bayer Says IUD Patients Have No Case
- Teva Agrees To Hold Off On Generic For Diabetes Drug Byetta
- Medicare Part A To Run Out Of Cash In 2028, Trustees Say
- Sandoz Misled About FDA Approval Of Drug, Competitors Say
- Dismissing Drug Design Defect Claims Based On Preemption
- From The Partner's Desk: Tips For Recent Law Grads
- Altaire Can't Dodge Claim GC Lied In Eye-Drop Supply Deal
- Ohio High Court Slams Judge's Overreach In Fen-Phen Case
- Full Fed. Circ. Won't Eye PTAB's Power To Start AIA Reviews
- Inside Trading Suspect's Death Ruled A Suicide
- Nanotech Firm Selecta Biosciences Nets $70M In Upsized IPO
- Atty-Client Privilege At Issue In Meningitis Bellwether
- Calif. Appeals Court Says Skin Care Labeling Deal Was Fair
- Eli Lilly Insurer Denied New Trial In $60M Drug Heist Suit
- Fed. Circ. Won't Revive Forehead Thermometer Patent
- Baxter Wins Chancery OK On New Board Terms, Voting Rules
- Chicago Says High Court Ruling Supports Its Opioid Suit
- Pharmacists Get Prison Over Tainted Compounding Drugs
- Feds Announce Arrests In $900M Medicare Fraud Takedown
- FDA Delay Of Drug Labeling Rule Is Bad News For Plaintiffs
- Alice Turns 2: Fed. Circ. Grapples With 'Implicit Exceptions'
- 'Taking My Talents To South Beach': Law Firm Version
- CVS Deal Would Make Memory Of Supplement Class Action
- Wal-Mart, Kmart, Rite Aid Escape Expired Drug FCA Suit
- FDA Warning Wire: Cancer Doc Targeted Over Plant Conditions
- Analogic Pays Feds $15M To End Russian Bribery Claims
- Sens. Slam 'Anti-Competitive' Wiley Rein Pharma Presentation
- NY Wholesaler Hits Allergan, Others With Antitrust Suit
- Florida Blue To Provide Costly Hep C Drug After Lawsuits
- Your 401(k) Plan: A Ticking Time Bomb Of Liability?
- GNC Investors Double Down In Illegal Supplements Suit
- Full Fed. Circ. Won't Review Generics Jurisdiction Ruling
- A Look At Fed. Circ. Induced Infringement Ruling In NuVasive
- Ex-Pfizer Worker Strikes Insider Trading Deal With SEC
- Not Guilty, Again: Individual Corporate Liability After Reichel
- Andrews Kurth Atty Defends Brief In $445M Dow IP Row
- Senate Rejects Gun Control Measures On DOJ Funding Bill
- Medical Device Maker Must Arbitrate Dispute, NJ Court Says
- Firms Must Plant Roots In These Cities To Compete Globally
- 4 Firms Lead The Pack In Global Expansion
- Law360 Reveals The Global 20 Firms Of 2016
- Ex-Acclarent Execs Slam Gov't's Tactics At Fraud Trial
- Justices Won't Take $4M Globus Medical Trade Secrets Row
- Shareholders Lose Suit Over Glaucoma Drug Trial
- FDA OKs First Human Trials For Zika Vaccine
- J&J Faces Breast-Growth Claims In 5th Philly Risperdal Trial
- Suboxone Buyers Slam Comparison To Sanofi's Antitrust Win
- High Court Seeks US Take On Sandoz-Amgen Biosimilar Battle
- Whistleblowers Lose 1st Circ. Appeal Of Novartis FCA Suit
- 4 Firms To Steer IPOs Led By Year's First VC 'Unicorn'
- Andrews Kurth Atty Can't Crash $446M Dow Row, Bayer Says
- 5 Escape Abbott's Test Strip RICO Suit With Settlement
- Ex-Womble Carlyle Atty Opens Shaw Fishman Del. Office
- Where Pay-For-Delay Stands 3 Years After Actavis
- Greenspoon's Cost Bid In $1.8M Stiefel ERISA Suit Too High
- Janssen Wants To Combine Celltrion Biosimilar Patent Suits
- Colo. Dispensary Urges State AG Intervention In Pot Tax Row
- FedEx Beats Drug Shipping Case As Charges Dropped Midtrial
- Health Hires: Quarles, Sheppard Mullin, Manatt Grow in DC
- Ex-Warner Chilcott Exec Acquitted In Doctor Bribery Scheme
- Alice Turns 2: A Survey Of The Impact Of A 'Minor Case'
- What To Expect From China's Drug Pricing Investigation
- Fed. Circ. Gives AIA Petitioners New Ways To Attack Patents
- Ranbaxy Can't Duck Antitrust Suit Over Generic Applications
- Atty Must Pay For Stolen Fen-Phen Funds: Ky. High Court
- Calif. Jury Finds For Flu Remedy Maker In False Ad Trial
- Health-Focused 1315 Capital Closes 1st Fund At $200M
- FDA Strengthens Kidney Warnings For Diabetes Medicines
- Rimon Adds 4 Partners From Arent, W&C, Sedgwick, Norris
- DJO, Ex-Workers Say Stryker's Poaching Suit Lacks Facts
- Bribery Case Against Ex-Warner Chilcott Exec Heads To Jury
- Senate Panel Moves To Ease Pot Banking Restrictions
- 2nd Circ. Urged To Revive Icahn 'Short-Swing' Trading Suit
- Expanded Access — A Regulatory Balancing Act For Drug Cos.
- Key Fixodent MDL Experts Properly Nixed, 11th Circ. Rules
- Boiron Moves To Toss False Ad Suit Over Flu Remedy Midtrial
- Frustrated FedEx Trial Judge Questions DEA Agent On Day 3
- Jones Day Nabs Tokyo IP Litigation Pro From Ropes & Gray
- Senate Dems' Gun Control Filibuster Halts Funding Debate
- Ferring, Allergan Patent Dispute Will Head To Trial: Judge
- 1st Circ. Won't Revisit $70M Biolitec Sanctions Cap
- J&J Unit Seeks To Boot Invokana Case From Pa. Courts
- Solazyme Urges 3rd Circ. To Back IP Rights Arbitration Award
- Policies Clash In $445M Dow Appeal, Andrews Kurth Atty Says
- KaloBios Plan Confirmed In Tumultuous Ch. 11 Case
- Reed Smith Adds PE, M&A Pro From Winston & Strawn In NY
- What FDA's Drug Distributor Licensing Regs Should Address
- Janssen Hits GE Unit With Patent Suit Over Biosimilar
- Medtronic Ruling Can Steer Transfer Pricing Tax Disputes
- Amneal Tells Fed Circ. Endo Played With Numbers In Patent
- Sens. Unveil New Bill Aimed To Help Generic Drug Flow
- US Weighs In On 1st Circ. Appeal Of Covidien FCA Suit
- Senate Gets Started On $56B Justice-Science-Commerce Bill
- Intuitive's Device Sent Metal To Patients' Brains, Suit Says
- SEC Sues Akebia Manager For Insider Trading On Drug Report
- Jailed Stock Scheme Atty Seeks Indictment Dismissal
- FDA Warning Wire: Sanitary Worries At Whole Foods Plant
- So Long, Seagate: A New Test For Willful Patent Infringement
- PTAB Evidence Rules Clarified, Affirming Genzyme Loss
- FDA OKs Food Draining Device To Treat Obesity
- FDA Issues Final Rule Allowing Symbols On Device Labels
- Warner Chilcott Wants 'Shotgun' Antitrust Claims Tossed
- 6 Factors Every Law Firm's Gender Diversity Initiative Needs
- Ex-Warner Chilcott Exec Says Feds' Jury Directions Flawed
- Patent Cases High Court May Review: Part 2
- Dozens Protest $11.75M Caldera Pelvic Mesh Deal
- Amazon, J&J, Others Pledge To Improve Wage Equality
- Hawaii Says It Can't Be Held To Plavix MDL Discovery Deal
- Firm Tells 3rd Circ. It Doesn't Owe Avandia MDL Fee
- Justices' Enhanced Damages Ruling Gives Patents More Teeth
- Fixodent Users Urge 11th Circ. To Reverse Experts' Exclusion
- Insurer Seeks To Cut Claims After Fresenius' $250M Deal
- 3rd Circ. Questions Allergan Antitrust Dismissal
- Rep Touted Acclarent Device After Promotion Ban, Jury Told
- Snooki, Diet Pill Co. Should Share Gov't Docs, Buyers Say
- FDA Actions 'Inadequate' On Powdered Caffeine, Group Says
- Attorneys React To High Court's Patent Damages Ruling
- Actos Direct Buyers Say Drug Mix Patent Can't Block Generic
- Judge Won't Stay J&J Hip Implant Trials After $502M Verdict
- The Bayer-Monsanto Deal Through An Antitrust Lens
- Shook Hardy Elects 1st Woman To Replace Longtime Leader
- Medivation Slams Sanofi's $9.3B Hostile Takeover Play
- Walgreens Ends Partnership With Blood Testing Co. Theranos
- Teva Halts Headache Patch Sales Amid Patient Burns
- Patent Cases High Court May Review: Part 1
- High Court Relaxes Standard For Enhanced Patent Damages
- Ex-U.S. Rep. To Lead BakerHostetler's Federal Policy Team
- Sex Pill Buyers Denied Cert. Under Spokeo In False Ad Row
- 9th Circ. Urged To Revive GNC Supplement RICO Class Action
- Buyers Say Gleevec Antitrust Suit Should Proceed
- Zimmer Win May Force Harder Look At Runaway Verdicts
- 2 Ex-InSys Staffers Charged Over Fentanyl Kickback Scheme
- Taxation With Representation: Gibson, White, Sheppard
- Purdue Resisting NH Opioid Marketing Probe, AG Says
- Merck To Pay Up To $1.25B For Neurogenic Biotech Afferent
- SEC Takes Off The Gloves Against Digital Casanova's Scheme
- Dental Laser Is Not An Unpatentable Law Of Nature: Judge
- Lone Pine Entered In Zimmer MDL Amid Atty Finger-Pointing
- Investor Sues Immunomedics Over Cancer Drug Misstatements
- Deals Rumor Mill: Bayer, Oaktree Capital, Valeant
- Colombia To Lower Price Of Novartis Cancer Drug Gleevec
- Mass. High Court To Mull VisionAid Counterclaim Coverage
- Chile Wants $15.5M Antitrust Fine For Pfizer Subsidiary
- 5th Circ. Gives Courts Powerful Tool To Enforce Daubert
- In-House Teams Are Voting With Their Feet — And Then Some
- 9th Circ. Probes DOJ On 'Troubling' Medicare Fraud Sentence
- Novartis Gets No Fees Despite 'Exceptional' Patent Case
- Off-Label Use Was Focus Of Training At Acclarent, Rep Says
- Mirena Users Say They Don't Need Experts To Beat Bayer
- Fed. Circ. Upholds Olympus Electrosurgery Patent Win
- Fed Circ. Won't Revive Ex-CEO's $4M Tax Refund Suit
- Potential Class Action Can Proceed In Celexa, Lexapro MDL
- Calif. High Court To Review Novartis Generic Drug Suit
- Royalty Rates in $1.3B Medtronic Row Nixed By Tax Court
- Bass Gets PTAB Review Of Fresenius Diprivan Patent
- FedEx Waives Jury On Eve Of Drug Trafficking Trial
- Boiron Tells False Ad Jury Flu Remedy Is Proven To Work
- 2 Biotechs Price $203M In Stock Offerings To Spur Pipelines
- Valeant Inks $54M Deal In DOJ's Salix Marketing Probe
- Inside Big Pharma's $70M Drug Pricing War In Calif.
- 9th Circ. Affirms Toss Of Suit Over Peregrine Drug Claims
- Ethicon's Own Rep. Said Mesh Degrades In Body, Patients Say
- NY Doctor Gets Prison In $100M Lab Test-Referral Scheme
- Biotech Co. Dodges Shareholder Suit Over 'Hyped' Drugs
- Marketing Came Before Research At Acclarent, Doc Testifies
- Biotech-Focused Longitude Capital Closes $525M Fund
- UPenn Trustees Call Inter Partes Reviews Unconstitutional
- 3rd Circ. Won't Take Second Look At Lovenox Antitrust Suit
- 7 Tips For Writing An Effective Amicus Brief
- The 25 Law Firms GCs Recommend To Their Friends
- 6 Funds Chip In $100M For 'Organism Design Co.' Startup
- Machine-Learning Algorithms Can Help Health Care Litigation
- 5 Insights From Garden City Group GC Scott Nader
- Sequenom Eyes Australia In Patent Row Over Fetal DNA Test
- Boiron Flu Remedy 'Expensive Sugar,' False Ad Jury Hears
- Murder, RICO Charges Remain In Meningitis Outbreak Suit
- J&J Unit Says $8.3M Hip Implant Verdict Inconsistent
- Trial Kicks Off Over Sanofi's IP Claims Over Generic Multaq
- Abbott Settles Depakote Suit As Jury Deliberates
- Ex-CEO Urges Fed. Circ. To Revive Bid For $4M Tax Refund
- FDA Warning Wire: Zimmer Biomet, Spotty Donor Screening
- FDA Can't OK More Crestor Generics, AstraZeneca Says
- Justices Urged To Clarify Natural Phenomena Patent Test
- NuVasive Can't Shake $28M Unfair Competition Verdict
- KaloBios Ties Up Loose Ends For Ch. 11 Plan Confirmation
- AngioScore's $20M Award Came In Wrong Suit, Fed. Circ. Told
- Baker & McKenzie Nabs Ex-K&L Gates Int'l Arbitration Pro
- Ex-Execs Blame FDA Rules In Off-Label Fraud Trial
- Anatomy Of A Merger: Grit Helps Shire Seal $32B Baxalta Buy
- White & Case Guides Zimmer Biomet In $1B Deal For LDR
- Russian Firm Hits Roche With Cancer Generics Antitrust Suit
- CPSC Urges Gov't To Sue Dr. Reddy's Over Drug Packaging
- Merck Atty's Lies Unravel $200M Patent Win Against Gilead
- Pfizer Opioid Meant To Deter Abuse Has Tampering Risk: FDA
- Greenspoon Marder Grows Cannabis Practice Across West
- 1st Circ. Urged To Revive CVS Vitamin E Label Suit
- Genentech, OSI Ink $67M FCA Deal Over Cancer Drug Claims
- Cancer-Focused Biotech Syros Files For $69M IPO
- J&J Won't Have To Avoid New Ads Before Liver Damage Trial
- Shkreli, Ex-Kaye Scholer Atty Deny New Fraud Charge
- Del. Justices Uphold $16M Caris Judgment In Split Decision
- Deals Rumor Mill: Pfizer, Constellis Holdings, Kuka
- Abbott Loses Final Appeal Of $3.4M Portuguese Antitrust Fine
- Actos Buyers Cite 2nd Circ. Libor Case In Antitrust Appeal
- Zimmer Gets $20M Knee Injury Verdict Trashed In Pa.
- Justices Refuse GSK's Appeal In Avandia RICO Case
- PE Investors Plug $100M Into NY-Based Cancer Treatment Co.
- High Court Seeks US Views On Lamictal Pay-For-Delay Case
- 5 Steps To An Anti-Corruption 'Culture Of Compliance'
- Ex-Stiefel CFO Urges Justices To Review Securities Fraud Suit
- Indivior Claims Victory In Patent Row With Actavis, Par
- Endo's AMS Settles More Than 100 Suits In Pelvic Mesh MDL
- Fed Circ. Backs NuVasive Surgical Patent Win Post-Commil
- Vermont Gov. Signs Drug Price Transparency Bill
- Cymbalta Users Urge Revival Of Drug's Withdrawal Claims
- Health Hires: Ex-HHS Atty Joins Hogan Lovells
- PTAB Will Review Eli Lilly's Patent For Cancer Drug Alimta
- Bayer Loses EPA Row Over Axed Pesticide
- Justices Told Hatch-Waxman Patent Safe Harbor Too Narrow
- Ex-Oppenheimer Adviser Charged With Insider Trading
- FDA Beats Spectrum Suit Over Fusilev Exclusivity At DC Circ.
- Ferring Hit With Class Action Over Weak IVF Drug
- 6 Supreme Court Cases Every BigLaw Attorney Should Watch
- How Eisai V. Sanofi Will Affect Loyalty Discount Cases
- Forest Escapes Class Cert. In Antidepressant Marketing MDL
- NantHealth's $91M Deal Leads 2 Biotech IPOs Totaling $141M
- Bristol-Myers Asks Calif. High Court To Block Plavix Suits
- KaloBios Puzzled By Hospital's Contract Decision Demand
- Teva Headache Patch Has Burned Many Patients, FDA Says
- Medical Device Co. Sued In Delaware Over Fee-Shifting Bylaw
- A Brief History Of Law Firm Cyberattacks
- 7th Circ. Urged To Review Disclosure-Only Settlements
- Mom Tells 6th Circ. Depakote Birth Defect Trial Court Erred
- Prior Art: When On Sale Is Not 'On Sale'
- BioScrip Board Shuffle Toppled Shareholder Suit, Judge Says
- Masimo Asks Justices To Review Arbitrator Bias Row
- Dow Urges Fed. Circ. To Nix $456M Patent Arbitration Award
- Valvoline Leads Way As 2 Cos. File For IPOs Totaling $150M
- In Rare Move, Judge Orders Zimmer Plaintiffs To Prove Cases
- Firm Says Jury Erred In Denying Claims For $1M In Legal Fees
- Drug Co. Hit With Class Action Over FDA Approval Claims
- CalPERS Backs Merck Investors In 3rd Circ. Tolling Fight
- Fla. Court OKs Stricter Expert Standard For Pending Cases
- Class Can't Redefine Trial Terms In Boiron False Ad Suit
- Shareholders Say Auspex CEO Rushed $3.5B Teva Merger
- Exergen Denied Enhanced Damages In $14.6M Patent Fight
- Feds Net $9M FCA Deal From Tenn. Drug Testing Co., Doc
- Ex-Execs Say 1st Amendment Protects Off-Label Promotion
- Pa. Readies 1st Interim Regulation For Medical Pot
- Patent Difficulties For 3-D Printed Medical Implants
- FDA's Opioid Implant Nod Shows Pressure To Curb Addiction